Top Markets
#1 Wrapped STX (Velar) Wrapped STX (Velar) +35.93%
#2 Siren Siren +30.58%
#3 Purr Purr +28.58%
#4 OriginTrail OriginTrail +23.69%
#5 UnifAI Network UnifAI Network +16.95%
#6 Wrapped XPL Wrapped XPL +16.15%
#7 Plasma Plasma +16.04%
#8 ApeX ApeX +15.83%
#9 龙虾 (Lobster) 龙虾 (Lobster) +14.86%
#10 DigiByte DigiByte +14.48%
Coin of the day
Wrapped STX (Velar) Wrapped STX (Velar)
Configurações
Idioma
PORTUGUêS
Moeda
USD
Tema
Hemab Therapeutics Holdings, Inc. Common Stock Hemab Therapeutics Holdings, Inc. Common Stock

Hemab Therapeutics Holdings, Inc. Common Stock

COAG
Classificação em ações #21709
Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology firm... Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology firm dedicated to transforming the treatment of blood coagulation disorders. Operating in the United States and Denmark, its mission is to enhance life and resilience for patients through innovative therapies. The company's leading pipeline candidate is HMB-001, a bispecific antibody. This asset is currently undergoing Phase 1/2 clinical trials for the preventive management of Glanzmann thrombasthenia and has progressed to Phase 2 for the prophylactic treatment of Factor VII deficiency. Additionally, Hemab is advancing HMB-002, a monovalent antibody, through Phase 1/2 clinical development. This drug is designed for the subcutaneous prophylactic treatment of Von Willebrand disease. Beyond these clinical assets, the company actively pursues numerous preclinical and discovery-stage programs. Established in 2020, Hemab Therapeutics Holdings, Inc. maintains its headquarters in Cambridge, Massachusetts.
Preço da ação
$50.82
Última sincronização: 2026-08-11
Valor de mercado
$102.09M
Variação (1 dia)
1.90%
Variação (1 ano)
-
País
US
Negociar Hemab Therapeutics Holdings, Inc. Common Stock (COAG)

Categoria

Healthcare
Receita da Hemab Therapeutics Holdings, Inc. Common Stock (COAG)
Receita em Aug 2026 TTM: 0
De acordo com os últimos relatórios financeiros da Hemab Therapeutics Holdings, Inc. Common Stock, a receita atual da empresa (TTM) é 0. Em 2026, a empresa obteve uma receita de 0 igual a a receita do ano 2026, que foi de 0. A receita é o valor total gerado pela venda de bens ou serviços. Ao contrário do lucro, nenhuma despesa é subtraída.
Histórico de receita da Hemab Therapeutics Holdings, Inc. Common Stock de 2026 a 2026
Receita no final de cada ano
Ano Receita Alterar
Não há dados suficientes para as datas fornecidas.
Receita de empresas similares ou concorrentes
Empresa Receita Diferença de Receita País
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH